NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.3 Antimetabolites > Lung cancer (non-small-cell, first line treatment) - pemetrexed - NICE TAG TA181

Lung cancer (non-small-cell, first line treatment) - pemetrexed - NICE TAG TA181

1.1 Pemetrexed in combination with cisplatin is recommended as an option for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.

1.2 People who are currently being treated with pemetrexed for NSCLC but who do not meet the criteria in 1.1 should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA181

Site by Devopa
© Copyright 2020 NHS. All rights reserved.